Inolimomab in steroid-refractory acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: retrospective analysis and comparison with other interleukin-2 receptor antibodies.

Background.The use of monoclonal antibodies against interleukin-2 receptor (IL-2R)-α chains could be an effective treatment of acute graft-versus-host disease (GvHD). Experimental model and clinical studies have reported various results.Methods.Inolimomab is a murine anti-IL-2R. Eighty-five patients